At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRBP Corbus Pharmaceuticals
Market Closed 12-20 16:00:00 EST
13.00
-0.33
-2.48%
盘后13.00
+0.000.00%
18:24 EST
High13.46
Low12.93
Vol1.01M
Open13.14
D1 Closing13.33
Amplitude3.98%
Mkt Cap158.33M
Tradable Cap100.85M
Total Shares12.18M
T/O13.25M
T/O Rate13.08%
Tradable Shares7.76M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Corbus Pharmaceuticals (CRBP) and Fortrea Holdings Inc. (FTRE)
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.